Mycophenolate mofetil in dermatomyositis: Is it safe?

被引：64

作者：

Rowin, J

Amato, AA

Deisher, N

Cursio, J

Meriggioli, MN

机构：

[1] Univ Illinois, EMG Lab, Dept Neurol & Rehabil, Inst Neuropsychiat,Sect Neuromuscular Dis, Chicago, IL 60612 USA

[2] Brigham & Womens Hosp, Neuromuscular Div, Dept Neurol, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Boston, MA USA

[4] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA

[5] Univ Illinois, Ctr Stroke Res, Chicago, IL 60612 USA

来源：

NEUROLOGY | 2006年 / 66卷 / 08期

关键词：

D O I：

10.1212/01.wnl.0000208416.32471.c0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Mycophenolate mofetil (MMF) is a potent immunosuppressive agent that inhibits proliferation of T and B lymphocytes. (1) MMF in the treatment of autoimmune disorders including the skin manifestations of dermatomyositis (DM), polymyositis, and myasthenia gravis(1-5) has been favorable, especially with regard to its safety profile. The mechanism of action of MMF suggests that it should be effective in DM, which has a humoral immune effector mechanism modulated mainly by CD4(+) dendritic cells. (6) However, there is little reported experience concerning the use of MMF in the treatment of the muscle manifestations of DM. (2,4) We report 10 cases of idiopathic DM with prominent muscle manifestations in which MMF was used in combination with corticosteroids.

引用

页码：1245 / 1247

页数：3

共 10 条

[1] Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases [J].

Chaudhry, V ;

Cornblath, DR ;

Griffin, JW ;

O'Brien, R ;

Drachman, DB .

NEUROLOGY, 2001, 56 (01) :94-96

[2] Does mycophenolate mofetil increase the incidence of infections in stable renal transplant recipients initially treated with a two-drug regimen? [J].

Chen, Y ;

Chu, SH ;

Wei, TY ;

Yen, TH ;

Chiang, YJ ;

Wu, CT ;

Chen, HW .

TRANSPLANTATION PROCEEDINGS, 2004, 36 (07) :2122-2123

[3] A CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN INFUSIONS AS TREATMENT FOR DERMATOMYOSITIS [J].

DALAKAS, MC ;

ILLA, I ;

DAMBROSIA, JM ;

SOUEIDAN, SA ;

STEIN, DP ;

OTERO, C ;

DINSMORE, ST ;

MCCROSKY, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (27) :1993-2000

[4]

Gelber AC, 2000, J RHEUMATOL, V27, P1542

[5] Interferon-α/β-mediated innate immune mechanisms in dermatomyositis [J].

Greenberg, SA ;

Pinkus, JL ;

Pinkus, GS ;

Burleson, T ;

Sanoudou, D ;

Tawil, R ;

Barohn, RJ ;

Saperstein, DS ;

Briemberg, HR ;

Ericsson, M ;

Park, P ;

Amato, AA .

ANNALS OF NEUROLOGY, 2005, 57 (05) :664-678

[6] Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy [J].

Majithia, V ;

Harisdangkul, V .

RHEUMATOLOGY, 2005, 44 (03) :386-389

[7] Opportunistic infections in polymyositis and dermatomyositis [J].

Marie, I ;

Hachulla, E ;

Chérin, P ;

Hellot, MF ;

Herson, S ;

Levesque, H ;

Hatron, PY .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (02) :155-165

[8] Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome [J].

Schnieder, C ;

Gold, R ;

Schäfers, M ;

Toyka, KV .

MUSCLE & NERVE, 2002, 25 (02) :286-288

[9]

Tausche AK, 2001, DERMATOLOGY, V202, P341

[10] Safety of mycophenolate mofetil versus azathioprine in renal transplantation: A systematic review [J].

Wang, K ;

Zhang, H ;

Li, Y ;

Wei, Q ;

Li, H ;

Yang, Y ;

Lu, Y .

TRANSPLANTATION PROCEEDINGS, 2004, 36 (07) :2068-2070

← 1 →